Avectas and UC Davis Collaborate on Cell Engineering Technology

Avectas today announced that it has entered into a collaborative agreement with The Simon Laboratory at UC Davis, California, USA to engage in the characterisation of cells engineered with Avectas' proprietary, non-viral SOLUPORE cell engineering platform. Under the collaboration, The Simon Laboratory at UCD will characterise cells engineered using SOLUPORE, leveraging UCD's unique cell membrane characterisation expertise and assays.

The collaboration will involve the transfer of Avectas' technology to The Simon Laboratory where the expert group will engineer immune cells and study the delivery of cargoes such as DNA, mRNA, proteins and gene editing tools to cells, while retaining high levels of cell viability and functionality, for autologous and allogeneic cell therapies. The outputs of this exciting collaboration will inform the development of next generation Cell and Gene therapies.

This collaboration builds on Avectas' recent developments including a partnership with Onk Therapeutics, Series C funding, the issuance of a key U.S. Patent (USPN 10,612,042) and new collaborations with Vycellix of Florida, USA, the Centre for Commercialization of Regenerative Medicine (CCRM) in Toronto, Canada and entering the new NK Cell Centre of Excellence at Karolinska Institute, Sweden, as a partner.



Related News